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Protein tyrosine phosphatases (PTPs) are important regulators of intracellular signaling
pathways via the dephosphorylation of phosphotyrosyl residues on various receptor and
non-receptor substrates.The phosphorylation state of central nervous system (CNS) signal-
ing components underlies the molecular mechanisms of a variety of physiological functions
including the control of energy balance and glucose homeostasis. In this review, we
summarize the current evidence implicating PTPs as central regulators of metabolism,
specifically highlighting their interactions with the neuronal leptin and insulin signaling path-
ways. We discuss the role of a number of PTPs (PTP1B, SHP2, TCPTP, RPTPe, and PTEN),
reviewing the findings from genetic mouse models and in vitro studies which highlight
these phosphatases as key central regulators of energy homeostasis.
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INTRODUCTION
Obesity is a major health issue within the United States with
current estimates at greater than one-third of the entire adult
US population diagnosed as obese (BMI≥ 30). When combined
with overweight individuals (BMI≥ 25), the prevalence estimates
reach nearly 70% of all US adults (Flegal et al., 2012). It has
become increasingly clear that obesity is not only a disorder of
peripheral physiology, but also a disease of the central nervous
system (CNS). Numerous cellular signals play a role in the central
regulation of body weight which can affect feeding and metabo-
lism, and dysregulation of their associated signaling pathways can
result in a bias toward weight gain. Phosphorylation is an impor-
tant regulatory mechanism of intracellular signaling pathways; the
opposing actions of kinase and phosphatase activity determine the
phosphorylation status of signaling components. Protein tyrosine
phosphatases (PTPs) dephosphorylate phosphotyrosyl residues on
a variety of receptor and non-receptor substrates. Within the past
decade, a number of PTPs [PTP1B, SHP2, TCPTP, Receptor-type
protein tyrosine phosphatase epsilon (RPTPe), and PTEN] have
been implicated in the central regulation of metabolism. This
review will focus on these PTPs in the CNS and explore their
roles in regulating metabolism via interactions with the leptin and
insulin signaling pathways.
LEPTIN AND INSULIN SIGNALING: REGULATION BY
TYROSINE PHOSPHORYLATION
Two metabolically relevant signaling pathways in the CNS are
the leptin and insulin signaling pathways. Both of these path-
ways are regulated largely by the reciprocal action of protein
tyrosine kinases (PTKs) and PTPs. Leptin is an adipocyte-derived
hormone which acts in the brain to control energy homeostasis.
Within the hypothalamus, leptin inhibits the orexigenic agouti-
related protein/neuropeptide Y-expressing (AgRP/NPY) neurons
and stimulates the anorexigenic proopiomelanocortin (POMC)-
expressing neurons, reducing food intake, and increasing energy
expenditure. Leptin signals through its receptor LepRb, a mem-
ber of the type-1 cytokine receptor family, which is associated
with the tyrosine kinase Janus kinase 2 (JAK2). When leptin binds
LepRb, JAK2 becomes activated, autophosphorylates, and phos-
phorylates several tyrosine residues along the intracellular tail of
the receptor. These include Y985, Y1077, and Y1138 which, when
phosphorylated, allow for recruitment of downstream signaling
effectors (reviewed in Bjørbaek and Kahn, 2004; Wauman and
Tavernier, 2011). Phosphorylation of these key tyrosine residues
along the LepRb activates separate arms of the leptin signaling
pathway, each contributing to leptin’s metabolic effects (Table 1).
Recently, the role of PTPs as regulators of central leptin signal-
ing has come to light, and a number of PTPs have been shown to
interact with LepRb signaling, positively or negatively regulating
its downstream signaling capacity.
Insulin is a pancreas-secreted hormone classically studied for
its ability to stimulate uptake of glucose and nutrients into periph-
eral target tissues. In the CNS however, insulin, like leptin, has been
shown to suppress body weight and food intake (Woods et al.,
1979; Air et al., 2002) and affect neuropeptide gene expression
and hypothalamic neuron activity (Schwartz et al., 1992; Benoit
et al., 2002; Choudhury et al., 2005). Similar to leptin signaling,
insulin receptor (IR) signaling relies on phosphotyrosyl residues
to elicit its downstream effects. In contrast to LepRb however,
the IR has intrinsic tyrosine kinase activity; upon ligand bind-
ing, the transmembrane β subunits of the IR autophosphorylate
on tyrosines Y1158, Y1162, and Y1163, recruiting downstream
effector proteins including insulin receptor substrate (IRS). IRS
becomes phosphorylated by IR on various Y residues and can
activate a number of downstream signaling pathways including
the phosphoinositide-3 kinase (PI3K)-Akt and MAPK pathways
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Table 1 | Summary of key tyrosine residues of leptin/insulin signaling components and their cellular/metabolic functions.
Leptin signaling component/
tyrosine involved
Cellular/metabolic function PTP involved/direction
of regulation
Select references
JAK2 Y1007/Y1008 Necessary PTK for phosphorylation of
intracellular tail of receptor
PTP1B(−) Myers et al. (2001), Zabolotny et al.
(2002), Cheng et al. (2002)
Involved in leptin-induced PI3K signaling via
IRS activation
RPTPe(−) Rousso-Noori et al. (2011)
LepRb Y985 Binding site for SHP2. Involved in activation
of MAPK pathway
SHP2(+) Björnholm et al. (2007), Bjorbak et al.
(2000)
Binding site for SOCS3. Involved in negative
feedback regulation of LepRb signaling
LepRb Y1077 Binding site for STAT5. Involved in energy
homeostasis/thermal regulation
ND Mütze et al. (2007), Gong et al. (2007)
LepRb Y1138 Binding site for STAT3. Involved in energy
homeostasis/melanocortin production
ND Bates et al. (2003)
STAT3 Y705 Transcription factor necessary for
leptin-induced changes in gene expression
TCPTP(−) Loh et al. (2011)
Insulin signaling component/
tyrosine involved
Cellular/metabolic function PTP involved/direction
of regulation
Select references
Insulin receptorβY1158 Receptor tyrosine kinase catalytic domain SHP2(±); RPTPe(−) Kharitonenkov et al. (1995), Møller
et al. (1995)
Insulin receptorβ
Y1162/Y1163
Receptor tyrosine kinase catalytic domain PTP1B(−);
TCPTP(−); RPTPe(−)
Salmeen et al. (2000), Galic et al.
(2003), Andersen et al. (2001)
IRS 1/2 various Y residues Necessary effector for protein-complex
formation and eliciting downstream PI3K
and MAPK signaling
PTP1B(−); SHP2(±) Goldstein et al. (2000), Asante-Appiah
and Kennedy (2003)
The PTPs involved in regulation at each site are listed and include PTPs that are currently known to have a role in the CNS regulation of energy balance. The direction
of PTP regulation indicates whether the specified PTP promotes (+) or inhibits (−) leptin or insulin signaling. ND, not determined.
(reviewed in White, 1997). Historically, much of what is known
regarding the cellular mechanisms underlying insulin signaling
has been studied within the periphery; the connection between
CNS insulin signaling and energy homeostasis is less well defined.
Neuron-specific IR knockout mice demonstrated genetic evidence
that central IR signaling plays an important role in regulating body
weight (Brüning et al., 2000). Furthermore, pharmacological stud-
ies have revealed that the reduction of food intake by acute central
insulin administration is PI3K-dependent (Niswender et al., 2003),
and in vitro models have identified the MAPK pathway as impor-
tant for insulin’s ability to regulate NPY/AgRP gene expression
(Mayer and Belsham, 2009). In contrast to the relatively recent
emergence of PTPs as regulators of central leptin signaling, many
PTPs have been historically linked to the insulin signaling path-
way, including PTP1B, SHP2, TCPTP, and PTEN. In spite of this,
their roles as regulators of central insulin signaling have yet to be
studied in depth.
Separate from the classical JAK2-STAT3, PI3K-Akt, and MAPK
pathways, leptin and insulin may mediate intracellular signal-
ing via other signaling proteins. For example, Tub is a protein
primarily expressed in the CNS which has been shown to be
phosphorylated by IR and JAK2 in vitro (Kapeller et al., 1999).
Targeted deletion of the tub gene in mice results in mature-onset
obesity with noticeable weight gain beginning at 8 weeks of age
(Stubdal et al., 2000). More recently, Tub has been implicated
in central insulin and leptin signaling in vivo; Tub appears to
act downstream of hypothalamic leptin and insulin signaling,
potentially as a transcription factor. Moreover, PTP1B may be a
negative regulator of CNS leptin and insulin signaling via direct
dephosphorylation of Tub (Prada et al., 2012). Thus, central leptin
and insulin can affect novel downstream effectors in addition to
JAK2/STAT3-, PI3K-, and MAPK-dependent signaling pathways,
and these distinct signaling proteins may be regulated by PTPs
such as PTP1B.
THE PTP SUPERFAMILY AND THE PROTOTYPIC PTP1B
The PTP superfamily consists of approximately 100 different PTPs
which can be divided into two groups: classical phospho-tyrosine
specific phosphatases and dual-specificity phosphatases. Classi-
cal PTPs only dephosphorylate phospho-tyrosine residues while
dual-specificity phosphatases can also dephosphorylate serine
and threonine residues. The classical, phospho-tyrosine specific
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phosphatases can further be subdivided into receptor-like and
soluble, non-transmembrane PTPs depending upon cellular local-
ization. All PTPs contain the (I/V)HCXXGXXR(S/T) active-site
motif with a conserved cysteine residue which is essential for
phosphate recognition and catalysis (reviewed in Tonks, 2003,
2006). Structural diversity within domains attached to the core
recognition motif defines a PTP’s substrate specificity and cel-
lular localization. Much of the understanding of PTP structure
and function has come from studies of protein tyrosine phos-
phatase 1B (PTP1B), the first PTP to be purified and to have its
crystal structure determined (Tonks et al., 1988; Barford et al.,
1994). Through the use of site-directed mutagenesis, catalytically
inactive “substrate-trapping” mutants were generated in order to
identify PTP1B targets (Flint et al., 1997). Substrate-trapping find-
ings combined with structural evidence led to the determination
that PTP1B preferentially binds to the tandem phospho-tyrosine
motif (E/D)-pY-pY-(R/K), due to the presence of an additional
phospho-tyrosine recognition site adjacent to its catalytic site.
PTP1B was shown to bind and dephosphorylate JAK2 prefer-
entially at pY1007/pY1008 (Myers et al., 2001), and the IR at
pY1162/pY1163 (Salmeen et al., 2000). Furthermore, it is also
likely that PTP1B can dephosphorylate IRS 1 (Goldstein et al.,
2000).
PTP1B was first implicated in the control of energy homeostasis
through the generation of PTP1B−/−mice (Table 2). PTP1B−/−
mice display resistance to diet-induced obesity and reduced adi-
posity due to increased energy expenditure, and improved periph-
eral glucose homeostasis as demonstrated by glucose and insulin
tolerance tests (Elchebly et al., 1999; Klaman et al., 2000). On a
high-fat diet, PTP1B−/− mice have decreased serum leptin lev-
els, suggesting that they might be leptin hypersensitive. Indeed,
PTP1B-deficiency improves leptin sensitivity both in vitro and
in vivo (Cheng et al., 2002; Zabolotny et al., 2002). Interestingly,
compound deletion of both leptin and PTP1B (ob/ob: Ptpn1−/−)
results in mice with attenuated weight gain in comparison to
leptin-deficient ob/ob mice, suggesting PTP1B may regulate leptin-
independent (e.g., central insulin signaling) pathways important
in the regulation of body weight (Cheng et al., 2002).
Generation of a number of tissue-specific PTP1B-deficient
mouse models has provided insight into PTP1B’s central metabolic
effects, separate from its functions at the periphery. Overall these
studies suggest that the reduction in body weight and adiposity
afforded by PTP1B-deficiency are a result of central loss of PTP1B.
Brain-specific PTP1B−/−mice (generated with a nestin-cre trans-
genic line) display improved body weight and adiposity compared
to controls on both chow and HFD; these mice have decreased food
intake, increased energy expenditure, and are leptin and insulin
hypersensitive (Bence et al., 2006). Mice deficient in PTP1B specif-
ically within POMC neurons (POMC-PTP1B−/−) also show
decreased body weight and adiposity, albeit only when fed a high-
fat diet, due to increased energy expenditure. Notably, on a chow
diet POMC-PTP1B−/− mice show improved glucose tolerance
and insulin sensitivity even when controlled for body weight and
adiposity, indicating that central PTP1B can regulate peripheral
glucose homeostasis (Banno et al., 2010). POMC-PTP1B−/−mice
also display enhanced leptin sensitivity within the hindbrain and
a heightened homeostatic response to cold exposure (De Jonghe
et al., 2011, 2012). More recently, LepRb-PTP1B−/− mice were
generated using a LepRb-cre line in which Cre recombinase is
specifically expressed within all LepRb-expressing neurons; mice
with LepRb-specific PTP1B-deficiency show reduced body weight
and adiposity compared to wild type controls on both chow and
HFD. These mice have slightly decreased food intake and slightly
elevated core temperature compared to controls. Consistent with
past findings, LepRb-PTP1B−/− mice are leptin hypersensitive
and show improved glucose homeostasis (Tsou et al., 2012). When
compared to a parallel line of global PTP1B−/− mice, LepRb-
PTP1B−/− mice on a high-fat diet show similar reductions in
body weight and leptin sensitivity, suggesting that the majority,
if not all, of these metabolic effects are due to a lack of PTP1B
within this subset of neurons. Whether any additional pathways
aside from those involving LepRb/JAK2 are involved in mediating
PTP1B’s effects in vivo remains to be determined.
In contrast to mouse models of central PTP1B-deficiency, liver-
and muscle-specific PTP1B deletion results in enhanced periph-
eral insulin sensitivity without effects on body weight or adiposity
(Delibegovic et al., 2007, 2009). Adipocyte-specific PTP1B dele-
tion has no effect on body weight or total adiposity, but increases
adipocyte size, circulating glucose and leptin levels (Owen et al.,
2012). In summary, these findings indicate PTP1B has CNS-
specific regulatory effects on body weight mediated via its interac-
tion with leptin signaling, and potentially by other as yet uniden-
tified pathways. In peripheral tissues such as muscle and liver,
PTP1B acts as a negative regulator of insulin signaling, resulting
in effects on glucose homeostasis. Whether or not PTP1B can reg-
ulate CNS insulin signaling to alter energy balance remains unclear
and warrants further investigation.
SHP2: POSITIVE REGULATOR OF LEPTIN RECEPTOR→MAPK
SIGNALING
SHP2 is an ubiquitously expressed Src homology 2 domain-
containing non-transmembrane protein tyrosine phosphatase
(Freeman et al., 1992). SHP2 contains two tandem src homology 2
(SH2) domains at its N-terminus which provide support for bind-
ing phosphotyrosyl residues. SHP2 has been shown to play a role in
numerous growth factor and cytokine-induced signaling pathways
and as mentioned earlier within the context of leptin signaling, is
a key intermediate for eliciting downstream MAPK signaling (via
binding Y985 of LepRb; Banks et al., 2000). Despite its role as a
tyrosine phosphatase and early in vitro evidence suggesting SHP2
can inhibit JAK2 activation or downregulate STAT3-mediated gene
transcription (Carpenter et al., 1998; Li et al., 1999), SHP2 has been
shown to ultimately promote leptin signaling within the CNS.
Interestingly in spite of its perceived “adaptor” role within lep-
tin signaling, SHP2’s phosphorylation and functional phosphatase
activity are required for leptin-induced ERK activation (Bjørbaek
et al., 2001). While global SHP2−/−mutation is embryonic lethal
in mice (Saxton et al., 1997), in 2004 a forebrain/neuronal-specific
SHP2−/− mouse model was generated using the CaMKIIα-cre
line, resulting in a pronounced obese phenotype. CaMKIIα-
SHP2−/− mice show increased body weight and adiposity com-
pared to wild type controls due to decreased energy expenditure.
These mice also display increased serum leptin, disrupted Npy
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Table 2 | Summary of CNS PTP-genetic mouse models and their associated metabolic phenotypes.
PTP mouse model Body weight/adiposity
phenotype
Leptin sensitivity Glucose homeostasis Reference
Global PTP1B−/− (whole body) Decreased Increased Improved GTT Klaman et al. (2000),
Elchebly et al. (1999)Improved ITT
Neuron-specific PTP1B −/−
(Nestin-Cre)
Decreased Increased Improved GTT Bence et al. (2006)
Improved ITT
POMC neuron-specific PTP1B−/−
(POMC-Cre)
Decreased Increased Improved GTT Banno et al. (2010)
Improved ITT
LepRb-specific PTP1B−/−
(LepRb-Cre)
Decreased Increased Improved GTT Tsou et al. (2012)
Forebrain-specific SHP2−/−
(CaMKIIα-Cre)
Increased Decreased (Fed) Hyperglycemia Zhang et al. (2004)
Hyperinsulinemia
Fatty liver
Brain-specific SHP2−/− (CRE3) Increased Decreased Impaired glucose tolerance Krajewska et al. (2008)
Hyperinsulinemia
POMC neuron-specific SHP2−/−
(POMC-Cre)
Increased Decreased Hyperinsulinemia Banno et al. (2010)
Impaired glucose tolerance
Forebrain-specific dominant-active
SHP2 (D61A)
Decreased in females Increased in females Improved GTT females He et al. (2012)
Improved ITT females
Neuron-specific TCPTP−/−
(Nestin-Cre)
Decreased Increased Improved GTT Loh et al. (2011)
Improved ITT
Neuron-specific
TCPTP−/−:PTP1B−/− (Nestin-Cre)
Decreased (additive
effects)
Increased (additive effects) Improved ITT (additive
effects)
Loh et al. (2011)
Global RPTPe−/− (whole body) Decreased in females Increased in females Improved GTT Rousso-Noori et al.
(2011)Improved ITT
LepRb-specific PTEN−/−
(LepRb-Cre)
Decreased Increased leptin-induced
PI3K pathway
Improved GTT Plum et al. (2007)
Improved ITT
Decreased serum insulin
LepRb-specific PTEN
overexpression (LepRb-Cre)
No change Decreased leptin-induced
PI3K pathway
Fatty liver Warne et al. (2011)
POMC-PTEN−/− (POMC-Cre) Increased, sex and
diet-dependent
Decreased food intake
suppression
ND Plum et al. (2006)
VMH-specific PTEN−/− (SF1-Cre) Increased ND ND Klöckener et al. (2011)
ND, not determined.
mRNA expression in response to fasting, elevated fed blood glu-
cose, and evidence of fatty liver. Additionally, CaMKIIα-SHP2−/−
mice show significantly reduced leptin-induced phosphorylated-
ERK within the arcuate nucleus, supporting SHP2’s role as a
positive regulator of leptin signaling via the MAPK pathway
(Zhang et al., 2004). Neuronal SHP2−/− mice developed using
a pan-neuronal Cre line, CRE3 (Banares et al., 2005) similarly
show an obese phenotype with increased body weight, adipos-
ity, hyperleptinemia, and diabetic symptoms (Krajewska et al.,
2008). Interestingly, CRE3-SHP2−/− mice are hyperphagic and
show disruptions in CNS leptin signaling distinct from those seen
in CaMKIIα-SHP2−/− mice. While CaMKIIα-SHP2−/− mice
have reduced leptin-induced ERK activation compared to wild
type controls, CRE3-SHP2−/− display elevated basal ERK phos-
phorylation which is decreased after leptin injection (Krajewska
et al., 2008). The phenotypic differences between the CaMKIIα-
SHP2−/− and the CRE3-SHP2−/−mouse models may be a result
of greater neuronal SHP2 deletion in the pan-neuronal CRE3
line. Using the transgenic CRE3 line, additional leptin-sensitive
regions involved in energy balance including the hindbrain are
targeted which may affect the resultant phenotype. Furthermore,
temporal differences in Cre expression due to different promot-
ers may also have an effect. The CaMKIIα promoter is known to
“turn on” Cre expression at P5 whereas the CRE3 line shows Cre
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expression as early as E11.5. As discussed further below, SHP2 is
involved in CNS development, thus temporal differences in SHP2
deletion could affect the development of feeding/satiety-related
neuronal circuits. Alternatively, differences in genetic background
of the mice in the two studies may account for any phenotypic
inconsistencies. Deletion of SHP2 from a specific neuronal popu-
lation, POMC-expressing cells, results in mice with increased body
weight, adiposity, and serum leptin levels on both chow and HFD.
Consistent with elevated serum leptin, POMC-SHP2−/− mice
display leptin resistance and impaired Pomc mRNA expression
(Banno et al., 2010). Like the CaMKIIα-SHP2−/−mice, POMC-
SHP2−/− mice show no changes in food intake but decreased
energy expenditure, likely explaining the increased weight gain.
POMC-SHP2−/−mice also show impairments in peripheral glu-
cose homeostasis compared to controls however when matched
for body weight and composition, no differences were observed,
indicating impairments to glucose homeostasis are secondary to
elevated body weight and adiposity of POMC-SHP2−/− mice
(Banno et al., 2010).
Recently, a transgenic SHP2 dominant-active (D61A) mutant
driven by the CaMKIIα promoter was generated. Given dele-
tion of SHP2 in post-mitotic forebrain neurons confers an obese
phenotype, one might expect a gain-of-function mutation to pro-
vide an improved metabolic phenotype. Interestingly, only female
SHP2D61A mice show resistance toward high-fat diet-induced obe-
sity, while male SHP2D61A mice gain weight similar to wild type
controls (He et al., 2012). Female SHP2D61A have decreased food
intake, increased energy expenditure, and improved leptin sen-
sitivity compared to controls. Additionally, SHP2 was found to
physically associate with estrogen receptor α, and leptin and estro-
gen stimulation synergistically enhanced ERK phosphorylation in
the brains of SHP2D61A mice compared to controls, explaining the
observed sex differences (He et al., 2012). The lack of a strong
metabolic phenotype in the SHP2-active mutant model suggests
SHP2’s ability to positively regulate leptin signaling may reach a
“ceiling effect” in its physiological benefit. It appears that enhanc-
ing the SHP2 arm of the leptin pathway results in an improved
metabolic phenotype in female mice due to coupled action with
estrogen, but the effects of SHP2 activation on energy balance
independent of estrogen may play a less prominent role than other
downstream leptin pathways (e.g., JAK2-STAT3 signaling). Muta-
tion of SHP2’s putative binding site on the LepRb, Y985, results
in a lean phenotype in young animals (Björnholm et al., 2007;
You et al., 2010), presumably due to the inability of SOCS3 to
inhibit leptin signaling. Thus, the obese phenotypes of neuronal
SHP2−/− models are possibly due to enhanced SOCS3 inhibi-
tion of leptin signaling (via binding Y985) rather than the loss of
downstream SHP2-mediated leptin signaling.
In addition to playing a positive role in transmitting down-
stream LepRb signals, SHP2 has also been implicated in neuronal
development via regulation of growth factor pathways. Deletion of
SHP2 in neuronal progenitors results in mice with early post-natal
lethality and disrupted corticogenesis (Ke et al., 2007), and expres-
sion of a dominant negative SHP2 mutant in cultured sympa-
thetic neurons results in decreased neurite outgrowth and survival
(Chen et al., 2002). Furthermore, POMC-SHP2−/− mice dis-
played a reduction inα-melanocyte-stimulating hormone (POMC
cleavage product) content in the periventricular nucleus and dorsal
medial hypothalamus, indicating SHP2 may influence the devel-
opment of hypothalamic feeding/satiety projections and circuits
(Banno et al., 2010). Overall, these findings suggest that impaired
central leptin signaling at least partially underlies the obese phe-
notypes of CNS-specific SHP2 knockout models. However, given
SHP2’s importance in neuronal development, subtle differences in
CNS-architecture in regions controlling energy balance may also
influence weight gain. In addition, SHP2 has been shown to act
as both a positive and negative regulator of insulin signaling in
different contexts (Asante-Appiah and Kennedy, 2003); whether
SHP2 mediates central effects of insulin on energy balance has not
been investigated.
TCPTP: NEGATIVE REGULATOR OF STAT3
T-cell PTP (TCPTP) is a ubiquitously expressed PTP which shares
a high-degree of sequence and structure homology with PTP1B.
Despite similarities, TCPTP and PTP1B have distinct substrate
specificity; TCPTP has been shown to target both JAK1 and
JAK3 (Simoncic et al., 2002), whereas PTP1B, as mentioned ear-
lier, directly dephosphorylates JAK2 (Myers et al., 2001; Cheng
et al., 2002; Zabolotny et al., 2002). Like PTP1B, TCPTP has also
been shown to negatively regulate insulin signaling via dephos-
phorylation of IRβ at Y1162/Y1163 (Galic et al., 2003), though
differential effects on intensity and duration of IR phosphoryla-
tion suggest TCPTP and PTP1B have non-redundant influences
on insulin signaling (Galic et al., 2005). TCPTP mRNA can be
alternatively spliced resulting in two different TCPTP isoforms of
different sizes: 48 kDa TC48 and 45 kDa TC45. The TC45 isoform
is localized to the nucleus and directly dephosphorylates IL-6-
induced pSTAT3 (Yamamoto et al., 2002; Tiganis and Bennett,
2007). Recently, in a comprehensive study by Loh et al. (2011) neu-
ronal TCPTP−/−mice were generated and presented a profound
metabolic phenotype, providing in vivo evidence that TCPTP can
regulate leptin-induced JAK/STAT signaling (Loh et al., 2011).
Neuronal TCPTP−/− mice show resistance to diet-induced obe-
sity, decreased adiposity on HFD, and increased energy expen-
diture. Interestingly, neuronal TCPTP−/− mice on chow have
decreased body weight but increased relative adiposity. In spite
of increased relative adiposity, neuronal TCPTP−/− mice have
decreased circulating leptin levels and improved leptin sensitiv-
ity, demonstrated both biochemically (increased leptin-induced
pSTAT3 levels in hypothalamus) as well as physiologically (greater
suppression of body weight/food intake). Alternatively, pharma-
cological inhibition of central TCPTP also improves leptin sensi-
tivity in wild type animals. Expression of TC45 substrate-trapping
mutant within LepRb-expressing CHO cells results in pSTAT3
accumulation in the nucleus, supporting the role of TCPTP as
a regulator of leptin signaling via dephosphorylation of STAT3.
Neuronal TCPTP−/− mice also show enhanced peripheral glu-
cose homeostasis as measured by glucose and insulin tolerance
tests (Loh et al., 2011).
Like PTP1B, TCPTP is induced by high-fat feeding implicat-
ing it in the pathogenesis of leptin resistance and obesity. In mice
fed HFD, PTP1B and SOCS3 were induced at 6 weeks of high-
fat feeding while TCPTP was induced at 9 weeks. Thus, increased
TCPTP may contribute to leptin resistance initially brought on by
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high levels of PTP1B and SOCS3 (Loh et al., 2011). Since PTP1B
and TCPTP act as negative regulators at different points within
the leptin signaling pathway, Loh et al. further examined whether
both enzymes could additively contribute to leptin resistance. Loh
et al. generated neuronal PTP1B−/−:TCPTP−/− double knock-
outs and found PTP1B−/−:TCPTP−/− mice are leaner on HFD
and more leptin hypersensitive than single PTP1B−/−mice, sug-
gesting the combined PTP1B/TCPTP deficiency synergistically
sensitizes leptin signaling. These results indicate that both PTP1B
and TCPTP can inhibit central leptin signaling via the dephos-
phorylation of JAK2 and STAT3, respectively and also leave open
the possibility that the two PTPs act within the same neuron
populations, inhibiting separate components of leptin signaling.
RPTPe: NEGATIVE REGULATOR OF JAK2
Receptor-type protein tyrosine phosphatase epsilon is transmem-
brane receptor-like PTP. Modification at the transcriptional or
post-transcriptional level can produce cytosolic, soluble forms of
the enzyme, affecting subcellular localization, and in turn sub-
strate specificity (Andersen et al., 2001; Gil-Henn et al., 2001). Both
RPTPe and cytosolic PTPe have been shown to negatively regulate
insulin signaling (Møller et al., 1995; Andersen et al., 2001; Aga-
Mizrachi et al., 2008), and cytosolic PTPe has been implicated
in inhibition of MAPK and JAK/STAT signaling (Tanuma et al.,
2000; Toledano-Katchalski et al., 2003). Recently, Rousso-Noori
et al. generated RPTPe-deficient mice by targeting the Ptpre gene
and removing three exons encoding amino acids common to both
RPTPe and soluble PTPe. Thus, RPTPe−/− mice are deficient in
all forms of the enzyme (Peretz et al., 2000; Rousso-Noori et al.,
2011). Although male RPTPe−/− mice display no body weight
differences compared to wild type controls, female RPTPe−/−
mice show resistance to diet-induced obesity with decreased body
weight and decreased adiposity and adipocyte size. In addition
to protection from HFD-induced weight gain, female RPTPe−/−
mice are resistant to weight gain after ovariectomy. RPTPe−/−
mice show no differences in food intake compared to wild type
controls, suggesting increased energy expenditure explains the lean
phenotype. Indeed, energy expenditure is increased in RPTPe−/−
mice compared to controls as determined by increased heat pro-
duction, oxygen consumption, and carbon dioxide production.
RPTPe−/− mice also show enhanced peripheral glucose home-
ostasis and cellular/physiological leptin sensitivity. Although all
RPTPe−/−mice show evidence of improved glucose metabolism,
only females show improved leptin sensitivity, consistent with the
sex differences in body weight and adiposity. Rousso-Noori et
al. examined potential RPTPe substrates within leptin signaling
in vitro and determined RPTPe directly interacts with JAK2, and
that the RPTPe-JAK2 complex coimmunoprecipitates with LepRb.
Furthermore, leptin-induced JAK2 activation results in phospho-
rylation of RPTPe on Y695, enhancing its ability to dephospho-
rylate JAK2 when compared to the non-phosphorylatable mutant
RPTPe Y695F, providing evidence that central leptin signaling can
regulate RPTPe activity via JAK2 phosphorylation. Based upon
these findings, Rousso-Noori et al. proposed a model in which
RPTPe plays a role as a negative feedback regulator of leptin
signaling via dephosphorylation of JAK2 (Rousso-Noori et al.,
2011).
Despite clear evidence of RPTPe as a JAK2-targeting
phosphatase, much remains unknown regarding its ability to
centrally regulate energy balance. The improved metabolic phe-
notype of RPTPe-deficiency shows clear sex differences with
females displaying greater metabolic benefits than males. As men-
tioned earlier at the level of leptin-induced SHP2-ERK activa-
tion, estrogen and leptin signaling exhibit substantial cross-talk;
in addition to SHP2, STAT3 has been shown to be a target of
estrogen receptor signaling (Gao and Horvath, 2008). There is
evidence of estrogen enhancing leptin sensitivity (Clegg et al.,
2006), therefore one could speculate that the enhanced leptin-
induced JAK2-STAT3 signaling in RPTPe-deficient mice may
elicit a greater physiological effect within females. Interestingly,
mice with PTP1B-deficiency demonstrate the reverse sex effect
with males displaying a stronger protective metabolic phenotype
despite both PTPs targeting JAK2. It will be interesting to deter-
mine the precise pattern of PTP expression within subsets of
energy balance neurons; perhaps RPTPe is enriched within estro-
gen receptor-expressing hypothalamic neurons whereas PTP1B
shows a separate pattern of hypothalamic expression. Further-
more, RPTPe has been implicated in neuronal excitability via mod-
ulation of voltage-gated potassium channels (Ebner-Bennatan
et al., 2012); however, how altered hypothalamic neuron excitabil-
ity can affect whole body energy homeostasis is an area of
continued investigation.
PTEN: NEGATIVE REGULATOR OF PI3K-Akt SIGNALING
Phosphatase and tensin homolog deleted on chromosome 10,
or PTEN, is a dual-specificity protein tyrosine phosphatase best
known for its role as a tumor suppressor (Li et al., 1997; Steck
et al., 1997). Although PTEN is a member of the PTPase family,
its primary physiological target appears to be the phospholipid
PIP3 rather than a tyrosine-phosphorylated protein (Maehama
and Dixon, 1998). Thus, PTEN opposes the action of PI3K by
directly dephosphorylating PIP3 into PIP2, acting as a downstream
negative regulator of both leptin and insulin signaling pathways.
Despite a clearly defined intracellular role for PTEN opposing
leptin- or insulin-stimulated PI3K signaling, its ability to centrally
regulate metabolism is less transparent due to contrasting pheno-
types of transgenic and mutant mouse models. LepRb-specific
deletion of PTEN results in decreased body weight, adiposity,
and adipocyte size in mice; food intake is unchanged, and oxy-
gen consumption is increased compared to controls (Plum et al.,
2007). Increased leptin-stimulated sympathetic nerve activation
and “browning” of perigonadal white adipose tissue in LepRb-
PTEN−/− mice also point toward increased energy expenditure
as the cause of leanness. The metabolic improvements seen in
LepRb-PTEN−/− mice are dependent on the presence of circu-
lating leptin as compound ob/ob:LepRb-PTEN−/− mice show a
comparable phenotype to ob/ob single mutants (Plum et al., 2007).
Surprisingly, LepRb-specific overexpression (OE) of PTEN in mice
does not result in an obese phenotype; instead, LepRb-PTEN-OE
mice display no difference in body weight, adiposity, or leptin lev-
els compared to controls. However, consistent with the findings
of Plum et al. (2007), attenuation of leptin-activated PI3K signal-
ing in LepRb-PTEN-OE mice increases liver triglycerides due to a
reduction in leptin-stimulated sympathetic nerve activity (Warne
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et al., 2011). Contrastingly, whole body PTEN-OE in mice results
in decreased body weight and adiposity due to increased energy
expenditure; however, the enhanced energy expenditure appears to
be a cell autonomous effect within hyperactive brown adipocytes
rather than CNS-related (Ortega-Molina et al., 2012).
In contrast to LepRb-PTEN−/−mice, POMC neuron-specific
PTEN deletion in mice unexpectedly results in a sexually dimor-
phic, diet-sensitive increase in body weight and hyperphagia.
Male POMC-PTEN−/− mice show a consistent increase in body
weight/adiposity on normal chow but no difference on HFD
compared to controls, while female mice only show a significant
obese phenotype on HFD. The phenotype of POMC-PTEN−/−
mice is a result of decreased POMC neuron excitability due to
heightened conductance of PIP3-sensitive, hyperpolarizing KATP
channels (Plum et al., 2006). The authors confirm that insulin
in fact hyperpolarizes POMC neuron membrane potential and
present a model where sensitization of insulin-activated PI3K sig-
naling in POMC neurons via targeted PTEN deletion results in
decreased POMC neuron excitability, ultimately promoting weight
gain. Interestingly, reduction of POMC neuron PI3K signaling via
deletion of the p110α catalytic subunit of PI3K within POMC
neurons also increases body weight and adiposity and reduces
energy expenditure in mice (Hill et al., 2009). This same discor-
dant trend is observed in targeted deletion of PTEN/p110 in the
ventral medial hypothalamus (VMH). PTEN-deficiency in SF1
neurons within the VMH results in increased body weight due
to hyperphagia (Klöckener et al., 2011). Klöckener et al. further
demonstrate that insulin-responsive SF1 neurons are inhibited by
insulin treatment, which is dependent upon KATP channel con-
ductance. Consistent with those findings, VMH-specific deletion
of IR yields a protective metabolic phenotype, and Klöckener et
al. provide convincing electrophysiological evidence that POMC
neuron activity is enhanced by attenuating insulin-stimulated
PI3K signaling in SF1 neurons, suggesting synaptic connectivity
between VMH neurons and arcuate POMC neurons. Like the
effects seen with POMC neuron-specific p110α deletion, VMH-
specific p110α deletion results in increased body weight gain
and adiposity on HFD due to decreased energy expenditure;
PI3K disruption in VMH also blunted the food intake sup-
pressing effects of leptin (Xu et al., 2010). These studies taken
together suggest that the activity of the PI3K pathway, as reg-
ulated by PTEN, has multiple and disparate effects on energy
homeostasis due to different cellular consequences (e.g., affect-
ing gene transcription or neuronal activity via KATP channels)
and is dependent upon neuronal identity (i.e., leptin- versus
insulin-responsive populations). The apparent contradiction of
increased PI3K pathway activation (via targeted PTEN deletion)
and decreased PI3K activation (via targeted p110α deletion) yield-
ing similar weight gain phenotypes implies that the active PI3K
pathway leads to at least two separate outputs which have oppos-
ing effects on energy balance. How these distinct outputs ulti-
mately result in the observed metabolic phenotype is unclear,
although variations in neuronal cell type could play a role.
Recently, Williams et al. demonstrated that leptin- and insulin-
responsive POMC neurons are segregated in distinct subpopula-
tions (Williams et al., 2010) which may explain inconsistencies
between LepRb- and POMC-specific PTEN knockout models.
Furthermore, limitations of current cre/loxp technology leading
to unexpected off target deletion (Padilla et al., 2010, 2012) may
contribute to the inconsistency between the PTEN mutant mouse
phenotypes. Careful dissection of downstream PI3K pathways will
be necessary in order to further reveal PTEN’s central metabolic
role.
PERSPECTIVES AND CONCLUSION
Protein tyrosine phosphatases play a major role in regulating path-
ways downstream of CNS leptin and insulin signaling; however,
much is still unknown regarding their ability to centrally regulate
energy balance, and a number of open questions remain in the
field. Specifically, in regards to insulin signaling, how PTPs inter-
act with IR signaling within the CNS remains largely unknown.
Although PTP1B, SHP2, TCPTP, and RPTPe have been shown
to negatively regulate IR signaling in the periphery, these PTPs
have not been specifically studied within the context of CNS
insulin signaling. One can speculate that inhibition of central
PTPs may sensitize central insulin signaling and promote weight
loss; however, the findings from the PTEN mouse models suggest
a more complex role for CNS insulin signaling. In addition to
leptin-like food intake reducing effects, central insulin can inhibit
neuronal electrical activity which may ultimately promote weight
gain. Additional analysis of the roles of specific PTPs in the con-
text of CNS leptin and insulin signaling is required to determine
their respective metabolic contribution. Furthermore, what gov-
erns PTP specificity when many PTPs seem to regulate the same
molecules downstream of leptin/insulin signaling? PTP1B, RPTPe,
and TCPTP all target the JAK2/STAT3 pathway, and JAK2 is a
direct substrate for both PTP1B and RPTPe (Figure 1). Plasma
membrane localization and tyrosine phosphorylation of RPTPe
serve to regulate its activity, whereas PTP1B is associated with the
endoplasmic reticulum and can be regulated by reversible oxida-
tion and a number of post-translational modifications (Yip et al.,
2010). Therefore, RPTPe and PTP1B may regulate LepRb-JAK2
signaling under distinct cellular contexts. Temporal regulation
based upon energy status and/or obesity pathology may also reg-
ulate PTP specificity as demonstrated by PTP1B and TCPTP’s
differential induction by HFD and leptin. Are PTPs differentially
expressed across populations of hypothalamic neurons? Given the
profound phenotypes in the various conditional, neuronal knock-
out models, many of the PTPs are expressed in the most commonly
studied POMC- and LepRb-expressing cells in the hypothalamus
suggesting some amount of overlap. However, careful analysis of
PTP expression within defined neuronal populations may reveal
important differences in PTP distribution. Unfortunately, the cur-
rent lack of effective antibodies for immunohistochemical stud-
ies has made answering the question of PTP CNS distribution
challenging.
Because of their central role in regulating metabolism, PTPs
are attractive targets for potential pharmacological intervention
in the treatment of obesity and type 2 diabetes. However, design-
ing small molecules to activate or inhibit specific PTPs presents
its own challenges. While genetic manipulation in mice pro-
duces profound metabolic phenotypes, the metabolic effects of
functional changes to PTPs in humans are unclear. Further-
more, attaining drug specificity is a major hurdle given PTPs
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FIGURE 1 | Model of PTP regulation of central leptin and insulin
signaling.When circulating leptin binds to its receptor LepRb, the
associated tyrosine kinase JAK2 autophosphorylates and phosphorylates
specific tyrosine residues along the intracellular tail of the LepRb.
Phosphorylation of Y985 allows for recruitment of the PTP SHP2 which
mediates downstream ERK1/2 signaling, while phosphorylation of Y1138
allows for activation of STAT3 which regulates transcription of key
neuropeptides involved in energy homeostasis. Unlike leptin signaling,
insulin binding to its receptor results in receptor autophosphorylation at
tyrosine residues 1158, 1162, and 1163. This allows for recruitment of the
effector IRS, which upon phosphorylation can recruit adaptor molecules
and mediate downstream PI3K and ERK1/2 signaling. In contrast to SHP2
which positively regulates leptin signaling, several PTPs can negatively
regulate central leptin and insulin signaling. PTP1B inhibits leptin and
insulin signaling by dephosphorylating JAK2 and the IR, respectively.
Additionally, PTP1B has been implicated in dephosphorylating the
downstream leptin/insulin signaling protein Tub. Like PTP1B, RPTPe has
been shown to inhibit leptin signaling at the level of JAK2, while TCPTP
negatively regulates leptin signaling via dephosphorylation of STAT3. PTEN
antagonizes neuronal insulin-induced PI3K signaling via dephosphorylation
of the phospholipid PIP3 into PIP2, resulting in decreased KATP channel
conductance.
can regulate different pathways dependent upon cell type. For
example, many of the PTPs in this review regulate growth factor-
activated pathways in which loss of function could have severe,
deleterious tumorigenic effects (e.g., PTEN). PTPs also play a
role in non-metabolic CNS functions which could yield poten-
tial side effects of drug action. As mentioned previously, SHP2
plays a role in CNS development; therefore, drug action may
result in unexpected and unwanted functional changes to neural
architecture. PTP1B expression has been shown to affect hip-
pocampal dendritic spine morphology. Interestingly, hippocam-
pus and cortex-specific PTP1B-deficient mice show an enhance-
ment in learning and memory tasks (Fuentes et al., 2012), sug-
gesting PTP1B inhibition may prove fruitful outside of enhancing
CNS leptin signaling. Future research is essential for clarifying
the metabolic and non-metabolic CNS signaling pathways that
are regulated by PTPs in order to advance effective therapeutic
development.
Although this review has focused the discussion of PTPs within
the context of central leptin and insulin signaling, other pathways
also contribute to central metabolism and are regulated by PTPs.
Obesity has been described as a chronic inflammatory disease,
and elevated circulating cytokines coincide with PTP expression
(Loh et al., 2011). Interleukin-6 and ciliary neurotrophic factor
have been shown to have leptin-like,CNS-specific weight-reducing
effects (Gloaguen et al., 1997; Lambert et al., 2001; Wallenius et al.,
2002a,b) and signal through the type-1 cytokine receptor subunit
gp130 which has been shown to transduce JAK/STAT signaling
(Heinrich et al., 1998). In addition to inflammatory cytokines,
brain-derived neurotrophic factor has been shown to affect food
intake and body weight (Nakagawa et al., 2002; Lebrun et al.,
2006; Unger et al., 2007), and the Trk receptor family have been
implicated as substrates of PTPs (Espanel et al., 2002). All in all,
PTPs clearly play a role in regulating metabolically relevant central
signaling pathways, however many details remain to be clarified.
Greater insights into how PTPs attain specificity, what other cen-
tral functions they have, and what other intracellular pathways
they regulate will allow us to thoroughly understand their role in
central metabolism.
Frontiers in Neuroscience | Neuroendocrine Science January 2013 | Volume 6 | Article 192 | 8
Tsou and Bence Central PTP regulation of metabolism
REFERENCES
Aga-Mizrachi, S., Brutman-Barazani, T.,
Jacob, A. I., Bak, A., Elson, A.,
and Sampson, S. R. (2008). Cytoso-
lic protein tyrosine phosphatase-
epsilon is a negative regulator of
insulin signaling in skeletal muscle.
Endocrinology 149, 605–614.
Air, E. L., Benoit, S. C., Blake Smith,
K. A, Clegg, D. J., and Woods, S.
C. (2002). Acute third ventricular
administration of insulin decreases
food intake in two paradigms. Phar-
macol. Biochem. Behav. 72, 423–429.
Andersen, J. N., Elson, A., Lammers, R.,
Rømer, J., Clausen, J. T., Møller, K.
B., et al. (2001). Comparative study
of protein tyrosine phosphatase-
epsilon isoforms: membrane local-
ization confers specificity in cellular
signalling. Biochem. J. 354, 581–590.
Asante-Appiah, E., and Kennedy, B.
P. (2003). Protein tyrosine phos-
phatases: the quest for negative regu-
lators of insulin action. Am. J. Phys-
iol. Endocrinol. Metab. 284, E663–
E670.
Banares, S., Zeh, K., Krajewska, M., Ker-
mer, P., Baribault, H., Reed, J. C., et
al. (2005). Novel pan-neuronal Cre-
transgenic line for conditional abla-
tion of genes in the nervous system.
Genesis 42, 6–16.
Banks, A. S., Davis, S. M., Bates, S. H.,
and Myers, M. G. (2000). Activation
of downstream signals by the long
form of the leptin receptor. J. Biol.
Chem. 275, 14563.
Banno, R., Zimmer, D., De Jonghe, B. C.,
Atienza, M., Rak, K., Yang, W., et al.
(2010). PTP1B and SHP2 in POMC
neurons reciprocally regulate energy
balance in mice. J. Clin. Invest. 120,
720–734.
Barford, D., Flint, A. J., and Tonks, N. K.
(1994). Crystal structure of human
protein tyrosine phosphatase 1B.
Science 263, 1397–1404.
Bates, S. H., Stearns, W. H., Dundon,
T. A., Schubert, M., Tso, A. W. K.,
Wang, Y., et al. (2003). STAT3 sig-
nalling is required for leptin reg-
ulation of energy balance but not
reproduction. Nature 421, 856–859.
Bence, K. K., Delibegovic, M., Xue, B.,
Gorgun, C. Z., Hotamisligil, G. S.,
Neel, B. G., et al. (2006). Neuronal
PTP1B regulates body weight, adi-
posity and leptin action. Nat. Med.
12, 917–924.
Benoit, S. C., Air, E. L., Coolen, L. M.,
Strauss, R., Jackman, A., Clegg, D.
J., et al. (2002). The catabolic action
of insulin in the brain is mediated
by melanocortins. J. Neurosci. 22,
9048–9052.
Bjørbaek, C., Buchholz, R. M., Davis,
S. M., Bates, S. H., Pierroz, D. D.,
Gu, H., et al. (2001). Divergent roles
of SHP-2 in ERK activation by lep-
tin receptors. J. Biol. Chem. 276,
4747–4755.
Bjørbaek, C., and Kahn, B. B. (2004).
Leptin signaling in the central
nervous system and the periph-
ery. Recent Prog. Horm. Res. 59,
305–331.
Bjorbak, C., Lavery, H. J., Bates, S. H.,
Olson, R. K., Davis, S. M., Flier, J. S.,
et al. (2000). SOCS3 mediates feed-
back inhibition of the leptin recep-
tor via Tyr985. J. Biol. Chem. 275,
40649–40657.
Björnholm, M., Münzberg, H., Leshan,
R. L., Villanueva, E. C., Bates, S.
H., Louis, G. W., et al. (2007).
Mice lacking inhibitory leptin recep-
tor signals are lean with normal
endocrine function. J. Clin. Invest.
117, 1354–1360.
Brüning, J. C., Gautam, D., Burks, D.
J., Gillette, J., Schubert, M., Orban,
P. C., et al. (2000). Role of brain
insulin receptor in control of body
weight and reproduction. Science
289, 2122–2125.
Carpenter, L. R., Farruggella, T. J.,
Symes, A, Karow, M. L., Yan-
copoulos, G. D., and Stahl, N.
(1998). Enhancing leptin response
by preventing SH2-containing phos-
phatase 2 interaction with Ob recep-
tor. Proc. Natl. Acad. Sci. U.S.A. 95,
6061–6066.
Chen, B., Hammonds-Odie, L., Per-
ron, J., Masters, B. A., and Bixby, J.
L. (2002). SHP-2 mediates target-
regulated axonal termination and
NGF-dependent neurite growth in
sympathetic neurons. Dev. Biol. 252,
170–187.
Cheng, A., Uetani, N., Simoncic, P. D.,
Chaubey,V. P., Lee-Loy,A., McGlade,
C. J., et al. (2002). Attenuation of lep-
tin action and regulation of obesity
by protein tyrosine phosphatase 1B.
Dev. Cell 2, 497–503.
Choudhury, A. I., Heffron, H., Smith,
M. A., Al-qassab, H., Xu, A. W., Sel-
man, C., et al. (2005). The role of
insulin receptor substrate 2 in hypo-
thalamic and β cell function. J. Clin.
Invest. 115, 940–950.
Clegg, D. J., Brown, L. M., Woods, S. C.,
and Benoit, S. C. (2006). Gonadal
hormones determine sensitivity to
central leptin and insulin. Diabetes
55, 978–987.
De Jonghe, B. C., Hayes, M. R., Banno,
R., Skibicka, K. P., Zimmer, D. J.,
Bowen, K. A., et al. (2011). Defi-
ciency of PTP1B in POMC neurons
leads to alterations in energy balance
and homeostatic response to cold
exposure. Am. J. Physiol. Endocrinol.
Metab. 300, E1002–E1011.
De Jonghe, B. C., Hayes, M. R., Zim-
mer, D. J., Kanoski, S. E., Grill, H. J.,
and Bence, K. K. (2012). Food intake
reductions and increases in ener-
getic responses by hindbrain lep-
tin and melanotan II are enhanced
in mice with POMC-specific PTP1B
deficiency.Am. J. Physiol. Endocrinol.
Metab. 303, E644–E651.
Delibegovic, M., Bence, K. K., Mody,
N., Hong, E. G., Ko, H. J., Kim, J.
K., et al. (2007). Improved glucose
homeostasis in mice with muscle-
specific deletion of protein-tyrosine
phosphatase 1B. Mol. Cell. Biol. 27,
7727.
Delibegovic, M., Zimmer, D., Kauff-
man, C., Rak, K., Hong, E., Cho, Y.,
et al. (2009). Liver-specific deletion
of protein-tyrosine phosphatase 1B
(PTP1B) improves metabolic syn-
drome and attenuates diet-induced
endoplasmic reticulum stress. Dia-
betes 58, 590–599.
Ebner-Bennatan, S., Patrich, E., Peretz,
A., Kornilov, P., Tiran, Z., Elson, A.,
et al. (2012). Multi-faceted modu-
lation of K+ channels by protein
tyrosine phosphatase epsilon tunes
neuronal excitability. J. Biol. Chem.
287, 27614–27628.
Elchebly, M., Payette, P., Michaliszyn,
E., Cromlish, W., Collins, S., Loy, A.
L., et al. (1999). Increased insulin
sensitivity and obesity resistance in
mice lacking the protein tyrosine
phosphatase-1B gene. Science 283,
1544–1548.
Espanel, X., Huguenin-Reggiani, M.,
and Hooft Van Huijsduijnen,
R. (2002). The SPOT tech-
nique as a tool for studying
protein tyrosine phosphatase sub-
strate specificities. Protein Sci. 11,
2326–2334.
Flegal, K. M., Carroll, M. D., Kit, B. K.,
and Ogden, C. L. (2012). Prevalence
of obesity and trends in the distri-
bution of body mass index among
US adults, 1999-2010. JAMA 307,
491–497.
Flint, A. J., Tiganis, T., Barford, D., and
Tonks, N. K. (1997). Development
of “substrate-trapping” mutants to
identify physiological substrates
of protein tyrosine phosphatases.
Proc. Natl. Acad. Sci. U.S.A. 94,
1680–1685.
Freeman, R. M., Plutzky, J., and Neel, B.
G. (1992). Identification of a human
src homology 2-containing protein-
tyrosine-phosphatase: a putative
homolog of Drosophila corkscrew.
Proc. Natl. Acad. Sci. U.S.A. 89,
11239–11243.
Fuentes, F., Zimmer, D., Atienza, M.,
Schottenfeld, J., Penkala, I., Bale,
T., et al. (2012). Protein tyrosine
phosphatase ptp1b is involved in
hippocampal synapse formation
and learning. PLoS ONE 7:e41536.
doi:10.1371/journal.pone.0041536
Galic, S., Hauser, C., Kahn, B. B., Haj,
F. G., Neel, B. G., Tonks, N. K., et
al. (2005). Coordinated regulation
of insulin signaling by the protein
tyrosine phosphatases PTP1B and
TCPTP. Mol. Cell. Biol. 25, 819–829.
Galic, S., Klingler-hoffmann, M.,
Michelle, T., Puryer, M. A., Meng,
T., Tonks, N. K., et al. (2003). Reg-
ulation of insulin receptor signaling
by the protein tyrosine phosphatase
TCPTP regulation of insulin recep-
tor signaling by the protein tyrosine
phosphatase TCPTP. Mol. Cell. Biol.
23, 2096–2108.
Gao, Q., and Horvath, T. L. (2008).
Cross-talk between estrogen and
leptin signaling in the hypothal-
amus. Am. J. Physiol. Endocrinol.
Metab. 294, E817–E826.
Gil-Henn, H., Volohonsky, G., and
Elson, A. (2001). Regulation of
protein-tyrosine phosphatases alpha
and epsilon by calpain-mediated
proteolytic cleavage. J. Biol. Chem.
276, 31772–31779.
Gloaguen, I., Costa, P., Demartis, A.,
Lazzaro, D., Di Marco, A., Graziani,
R., et al. (1997). Ciliary neurotrophic
factor corrects obesity and diabetes
associated with leptin deficiency and
resistance. Proc. Natl. Acad. Sci.
U.S.A. 94, 6456–6461.
Goldstein, B. J., Bittner-Kowalczyk, A,
White, M. F., and Harbeck, M.
(2000). Tyrosine dephosphorylation
and deactivation of insulin recep-
tor substrate-1 by protein-tyrosine
phosphatase 1B. Possible facilitation
by the formation of a ternary com-
plex with the Grb2 adaptor protein.
J. Biol. Chem. 275, 4283–4289.
Gong, Y., Ishida-Takahashi, R., Vil-
lanueva, E. C., Fingar, D. C.,
Münzberg, H., and Myers, M. G.
(2007). The long form of the lep-
tin receptor regulates STAT5 and
ribosomal protein S6 via alternate
mechanisms. J. Biol. Chem. 282,
31019–31027.
He, Z., Zhang, S. S., Meng, Q., Li, S., Zhu,
H. H., Raquil, M.-A., et al. (2012).
Shp2 controls female body weight
and energy balance by integrating
leptin and estrogen signals.Mol.Cell.
Biol. 32, 1867–1878.
Heinrich, P. C., Behrmann, I., Müller-
Newen, G., Schaper, F., and Graeve,
L. (1998). Interleukin-6-type
cytokine signalling through the
gp130/Jak/STAT pathway. Biochem.
J. 334(Pt 2), 297–314.
Hill, J. W., Xu, Y., Preitner, F., Fukuda,
M., Cho, Y.-R., Luo, J., et al.
www.frontiersin.org January 2013 | Volume 6 | Article 192 | 9
Tsou and Bence Central PTP regulation of metabolism
(2009). Phosphatidyl inositol 3-
kinase signaling in hypothalamic
proopiomelanocortin neurons con-
tributes to the regulation of glucose
homeostasis. Endocrinology 150,
4874–4882.
Kapeller, R., Moriarty, A., Strauss, A.,
Stubdal, H., Theriault, K., Siebert, E.,
et al. (1999). Tyrosine phosphoryla-
tion of tub and its association with
Src homology 2 domain-containing
proteins implicate tub in intracellu-
lar signaling by insulin. J. Biol. Chem.
274, 24980–24986.
Ke, Y., Zhang, E. E., Hagihara, K., Wu,
D., Pang, Y., Klein, R., et al. (2007).
Deletion of Shp2 in the brain leads to
defective proliferation and differen-
tiation in neural stem cells and early
postnatal lethality.Mol. Cell. Biol. 27,
6706–6717.
Kharitonenkov, A., Schnekenburger,
J., Chen, Z., Knyazev, P., Ali, S.,
Zwick, E., et al. (1995). Adapter
function of protein-tyrosine
phosphatase 1D in insulin recep-
tor/insulin receptor substrate-1
interaction. J. Biol. Chem. 270,
29189–29193.
Klaman, L. D., Sharpe, A. H., Boss, O.,
Stricker-Krongrad, A., Peroni, O. D.,
Kim, J. K., et al. (2000). Increased
energy expenditure, decreased adi-
posity, and tissue-specific insulin
sensitivity in protein-tyrosine phos-
phatase 1B-deficient mice. Mol. Cell.
Biol. 20, 5479–5489.
Klöckener, T., Hess, S., Belgardt, B.
F., Paeger, L., Verhagen, L. A. W.,
Husch, A., et al. (2011). High-fat
feeding promotes obesity via insulin
receptor/PI3K-dependent inhibi-
tion of SF-1 VMH neurons. Nat.
Neurosci. 14, 911–918.
Krajewska, M., Banares, S., Zhang, E.
E., Huang, X., Scadeng, M., Jhala,
U. S., et al. (2008). Development
of diabesity in mice with neu-
ronal deletion of Shp2 tyrosine
phosphatase. Am. J. Pathol. 172,
1312–1324.
Lambert, P. D., Anderson, K. D., Slee-
man, M. W., Wong, V., Tan, J.,
Hijarunguru,A., et al. (2001). Ciliary
neurotrophic factor activates leptin-
like pathways and reduces body fat,
without cachexia or rebound weight
gain, even in leptin-resistant obe-
sity. Proc. Natl. Acad. Sci. U.S.A. 98,
4652–4657.
Lebrun, B., Bariohay, B., Moyse, E.,
and Jean, A. (2006). Brain-derived
neurotrophic factor (BDNF) and
food intake regulation: a minireview.
Auton. Neurosci. 126–127, 30–38.
Li, C., Friedman, J. M., and Riedman,
M. F. (1999). Leptin receptor acti-
vation of SH2 domain containing
protein tyrosine phosphatase 2 mod-
ulates Ob receptor signal transduc-
tion. Proc. Natl. Acad. Sci. U.S.A. 96,
9677–9682.
Li, J., Yen, C., Liaw, D., Podsypanina, K.,
Bose, S., Wang, S. I., et al. (1997).
PTEN, a putative protein tyrosine
phosphatase gene mutated in human
brain, breast, and prostate cancer.
Science 275, 1943–1947.
Loh, K., Fukushima,A., Zhang, X., Galic,
S., Briggs, D., Enriori, P. J. J., et
al. (2011). Elevated hypothalamic
TCPTP in obesity contributes to cel-
lular leptin resistance.CellMetab. 14,
684–699.
Maehama, T., and Dixon, J. (1998). The
tumor suppressor, PTEN/MMAC1,
dephosphorylates the lipid second
messenger, phosphatidylinositol 3,
4, 5-trisphosphate. J. Biol. Chem.
13375–13378.
Mayer, C. M., and Belsham, D. D.
(2009). Insulin directly regulates
NPY and AgRP gene expression
via the MAPK MEK/ERK signal
transduction pathway in mHypoE-
46 hypothalamic neurons. Mol. Cell.
Endocrinol. 307, 99–108.
Møller, N. P., Møller, K. B., Lammers,
R., Kharitonenkov, A., Hoppe, E.,
Wiberg, F. C., et al. (1995). Selec-
tive down-regulation of the insulin
receptor signal by protein-tyrosine
phosphatases alpha and epsilon. J.
Biol. Chem. 270, 23126–23131.
Mütze, J., Roth, J., Gerstberger, R.,
and Hübschle, T. (2007). Nuclear
translocation of the transcription
factor STAT5 in the rat brain after
systemic leptin administration.Neu-
rosci. Lett. 417, 286–291.
Myers, M. P., Andersen, J. N., Cheng,
A., Tremblay, M. L., Horvath, C.
M., Parisien, J. P., et al. (2001).
TYK2 and JAK2 are substrates of
protein-tyrosine phosphatase 1B. J.
Biol. Chem. 276, 47771–47774.
Nakagawa, T., Ono-Kishino, M., Sug-
aru, E., Yamanaka, M., Taiji, M., and
Noguchi, H. (2002). Brain-derived
neurotrophic factor (BDNF) regu-
lates glucose and energy metabolism
in diabetic mice. Diabetes Metab.
Res. Rev. 18, 185–191.
Niswender, K. D., Morrison, C. D.,
Clegg, D. J., Olson, R., Baskin, D.
G., Myers, M. G. J., et al. (2003).
Insulin activation of phosphatidyli-
nositol 3-kinase in the hypothalamic
arcuate nucleus: a key mediator of
insulin-induced anorexia. Diabetes
52, 227–231.
Ortega-Molina, A., Efeyan, A., Lopez-
Guadamillas, E., Muñoz-Martin, M.,
Gómez-López, G., Cañamero, M.,
et al. (2012). Pten positively regu-
lates brown adipose function, energy
expenditure, and longevity. Cell
Metab. 15, 382–394.
Owen, C., Czopek, A., Agouni, A.,
Grant, L., Judson, R., Lees, E. K.,
et al. (2012). Adipocyte-specific
protein tyrosine phosphatase
1B deletion increases lipogen-
esis, adipocyte cell size and is
a minor regulator of glucose
homeostasis. PLoS ONE 7:e32700.
doi:10.1371/journal.pone.0032700
Padilla, S. L., Carmody, J. S., and Zeltser,
L. M. (2010). Pomc-expressing prog-
enitors give rise to antagonistic
neuronal populations in hypothala-
mic feeding circuits. Nat. Med. 16,
403–405.
Padilla, S. L., Reef, D., and Zeltser, L.
M. (2012). Defining POMC neurons
using transgenic reagents: impact of
transient Pomc expression in diverse
immature neuronal populations.
Endocrinology 153, 1219–1231.
Peretz, A., Gil-Henn, H., Sobko, A.,
Shinder, V., Attali, B., and Elson,
A. (2000). Hypomyelination and
increased activity of voltage-gated
K+ channels in mice lacking pro-
tein tyrosine phosphatase epsilon.
EMBO J. 19, 4036–4045.
Plum, L., Ma, X., Hampel, B., Balthasar,
N., Coppari, R., Münzberg, H., et
al. (2006). Enhanced PIP3 signal-
ing in POMC neurons causes KATP
channel activation and leads to diet-
sensitive obesity. J. Clin. Invest. 116,
1886–1901.
Plum, L., Rother, E., Münzberg, H.,
Wunderlich, F. T., Morgan, D. A.,
Hampel, B., et al. (2007). Enhanced
leptin-stimulated Pi3k activation in
the CNS promotes white adipose tis-
sue transdifferentiation. Cell Metab.
6, 431–445.
Prada, P. O., Quaresma, P. G. F., Caricilli,
A. M., Santos, A. C., Guadagnini, D.,
Morari, J., et al. (2012). Tub has a key
role in insulin and leptin signaling
and action in vivo in hypothalamic
nuclei. Diabetes 62, 137–148.
Rousso-Noori, L., Knobler, H.,
Levy-Apter, E., Kuperman, Y.,
Neufeld-Cohen, A., Keshet, Y.,
et al. (2011). Protein tyrosine
phosphatase epsilon affects body
weight by downregulating leptin
signaling in a phosphorylation-
dependent manner. Cell Metab. 13,
562–572.
Salmeen, A., Andersen, J. N., Myers,
M. P., Tonks, N. K., and Barford,
D. (2000). Molecular basis for the
dephosphorylation of the activa-
tion segment of the insulin receptor
by protein tyrosine phosphatase 1B.
Mol. Cell 6, 1401–1412.
Saxton, T. M., Henkemeyer, M., Gasca,
S., Shen, R., Rossi, D. J., Shalaby, F., et
al. (1997). Abnormal mesoderm pat-
terning in mouse embryos mutant
for the SH2 tyrosine phosphatase
Shp-2. EMBO J. 16, 2352–2364.
Schwartz, M. W., Sipols, A. J., Marks,
J. L., Sanacora, G., White, J. D.,
Scheurink, A., et al. (1992). Inhi-
bition of hypothalamic neuropep-
tide Y gene expression by insulin.
Endocrinology 130, 3608–3616.
Simoncic, P. D., Lee-Loy, A., Barber, D.
L., Tremblay, M. L., and McGlade, C.
J. (2002). The T cell protein tyrosine
phosphatase is a negative regulator
of janus family kinases 1 and 3. Curr.
Biol. 12, 446–453.
Steck, P. A., Pershouse, M. A., Jasser,
S. A., Yung, W. K., Lin, H., Ligon,
A. H., et al. (1997). Identification
of a candidate tumour suppres-
sor gene, MMAC1, at chromosome
10q23.3 that is mutated in multi-
ple advanced cancers.Nat. Genet. 15,
356–362.
Stubdal, H., Lynch, C. A., Moriarty, A.,
Fang, Q., Chickering, T., Deeds, J. D.,
et al. (2000). Targeted deletion of the
tub mouse obesity gene reveals that
tubby is a loss-of-function mutation.
Mol. Cell. Biol. 20, 878–882.
Tanuma, N., Nakamura, K., Shima, H.,
and Kikuchi, K. (2000). Protein-
tyrosine phosphatase PTPepsilon C
inhibits Jak-STAT signaling and dif-
ferentiation induced by interleukin-
6 and leukemia inhibitory factor in
M1 leukemia cells. J. Biol. Chem. 275,
28216–28221.
Tiganis, T., and Bennett, A. M. (2007).
Protein tyrosine phosphatase func-
tion: the substrate perspective.
Biochem. J. 402, 1–15.
Toledano-Katchalski, H., Kraut, J., Sines,
T., Granot-Attas, S., Shohat, G., Gil-
Henn, H., et al. (2003). Protein tyro-
sine phosphatase epsilon inhibits
signaling by mitogen-activated pro-
tein kinases. Mol. Cancer Res. 1,
541–550.
Tonks, N. (2003). PTP1B: from the side-
lines to the front lines! FEBS Lett.
546, 140–148.
Tonks, N. K. (2006). Protein tyrosine
phosphatases: from genes, to func-
tion, to disease. Nat. Rev. Mol. Cell
Biol. 7, 833–846.
Tonks, N. K., Diltz, C. D., and
Fischer, E. H. (1988). Purifica-
tion of the major protein-tyrosine-
phosphatases of human placenta. J.
Biol. Chem. 263, 6722–6730.
Tsou, R. C., Zimmer, D. J., De Jonghe,
B. C., and Bence, K. K. (2012).
Deficiency of PTP1B in leptin
receptor-expressing neurons leads
to decreased body weight and adi-
posity in mice. Endocrinology 153,
1–11.
Frontiers in Neuroscience | Neuroendocrine Science January 2013 | Volume 6 | Article 192 | 10
Tsou and Bence Central PTP regulation of metabolism
Unger, T. J., Calderon, G. A., Bradley, L.
C., Sena-Esteves, M., and Rios, M.
(2007). Selective deletion of Bdnf in
the ventromedial and dorsomedial
hypothalamus of adult mice results
in hyperphagic behavior and obesity.
J. Neurosci. 27, 14265–14274.
Wallenius, K., Wallenius, V., Sunter,
D., Dickson, S. L., and Jansson,
J.-O. (2002a). Intracerebroven-
tricular interleukin-6 treatment
decreases body fat in rats. Biochem.
Biophys. Res. Commun. 293,
560–565.
Wallenius, V., Wallenius, K., Ahrén, B.,
Rudling, M., Carlsten, H., Dickson,
S. L., et al. (2002b). Interleukin-6-
deficient mice develop mature-onset
obesity. Nat. Med. 8, 75–79.
Warne, J. P., Alemi, F., Reed, A. S.,
Varonin, J. M., Chan, H., Piper, M.
L., et al. (2011). Impairment of cen-
tral leptin-mediated PI3K signaling
manifested as hepatic steatosis inde-
pendent of hyperphagia and obesity.
Cell Metab. 14, 791–803.
Wauman, J., and Tavernier, J. (2011).
Leptin receptor signaling: pathways
to leptin resistance. Front. Biosci. 16,
2771–2793.
White, M. F. (1997). The insulin sig-
nalling system and the IRS pro-
teins. Diabetologia 40(Suppl. 2),
S2–S17.
Williams, K. W., Margatho, L. O., Lee,
C. E., Choi, M., Lee, S., Scott, M. M.,
et al. (2010). Segregation of acute
leptin and insulin effects in distinct
populations of arcuate proopiome-
lanocortin neurons. J. Neurosci. 30,
2472–2479.
Woods, S. C., Lotter, E. C., McKay, L.
D., and Porte, D. (1979). Chronic
intracerebroventricular infusion of
insulin reduces food intake and
body weight of baboons.Nature 282,
503–505.
Xu, Y., Hill, J. W., Fukuda, M., Gautron,
L., Sohn, J.-W., Kim, K.-W., et al.
(2010). PI3K signaling in the ven-
tromedial hypothalamic nucleus is
required for normal energy home-
ostasis. Cell Metab. 12, 88–95.
Yamamoto, T., Sekine, Y., Kashima,
K., Kubota, A., Sato, N., Aoki, N.,
et al. (2002). The nuclear isoform
of protein-tyrosine phosphatase
TC-PTP regulates interleukin-
6-mediated signaling pathway
through STAT3 dephosphorylation.
Biochem. Biophys. Res. Commun.
297, 811–817.
Yip, S.-C., Saha, S., and Chernoff, J.
(2010). PTP1B: a double agent in
metabolism and oncogenesis.Trends
Biochem. Sci. 1–8.
You, J., Yu, Y., Jiang, L., Li, W., Yu, X.,
Gonzalez, L., et al. (2010). Signaling
through Tyr985 of leptin receptor as
an age/diet-dependent switch in the
regulation of energy balance. Mol.
Cell. Biol. 30, 1650–1659.
Zabolotny, J. M., Bence-Hanulec, K.
K., Stricker-Krongrad, A., Haj, F.,
Wang, Y., Minokoshi, Y., et al.
(2002). PTP1B regulates leptin sig-
nal transduction in vivo. Dev. Cell 2,
489–495.
Zhang, E. E., Chapeau, E., Hagihara,
K., and Feng, G.-S. (2004). Neu-
ronal Shp2 tyrosine phosphatase
controls energy balance and metab-
olism. Proc. Natl. Acad. Sci. U.S.A.
101, 16064–16069.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 05 October 2012; paper pend-
ing published: 26 October 2012; accepted:
17 December 2012; published online: 07
January 2013.
Citation: Tsou RC and Bence
KK (2013) Central regulation of
metabolism by protein tyrosine phos-
phatases. Front. Neurosci. 6:192. doi:
10.3389/fnins.2012.00192
This article was submitted to Frontiers
in Neuroendocrine Science, a specialty of
Frontiers in Neuroscience.
Copyright © 2013 Tsou and Bence. This
is an open-access article distributed under
the terms of the Creative Commons Attri-
bution License, which permits use, distri-
bution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org January 2013 | Volume 6 | Article 192 | 11
